Newsfeeds Archive - Spark Newswire

2 minute read

Why Is German Biotech Affimed Stock Soaring On Monday?

June 3, 2:13 PM

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.

AFMD

4 minute read

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

June 3, 1:56 PM

Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9%…

ADRT

2 minute read

News

Why Affimed Shares Are Soaring

By Erica Kollmann

June 3, 12:58 PM

Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).

AFMD

1 minute read

Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress

By Benzinga Newsdesk

May 14, 10:12 AM

Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse

AFMD

5 minute read

Earnings

Earnings Scheduled For March 28, 2024

By Benzinga Insights

March 28, 5:24 AM

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.

ACHV

1 minute read

Earnings

A Preview Of Affimed’s Earnings

By Benzinga Insights

March 27, 11:01 AM

Affimed (NASDAQ:AFMD) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here’s what investors need…

AFMD

2 minute read

Affimed Provides Clinical Response Update On AFM24-102 Trial In EGFR-Wildtype Non-Small Cell Lung Cancer

By Benzinga Newsdesk

January 8, 5:16 PM

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three of the initially

AFMD

3 minute read

Affimed Announces Leadership Change And Organizational Restructuring; Dr. Adi Hoess To Step Down As CEO And Management Board Member; Dr. Andreas Harstrick Appointed Interim CEO; Strategic Restructuring Reducing Headcount By Up To 50%

By Benzinga Newsdesk

January 8, 9:29 AM

Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go forward organization

AFMD